Scientists hope to develop new treatments for ovarian cancer after discovering how genes become resistant to many drugs.
A gene called ABCB1, which is known to play a role in resistance to the chemotherapy drug paclitaxel in ovarian cancers, also causes resistance to other ovarian treatments, researchers at the University of Dundee have found.
Women with ovarian cancer are commonly treated with a combination of carboplatin and paclitaxel, but if the cancer becomes resistant another group of drugs called PARP inhibitors are a common alternative.
Read more: 94 per cent of cancer patients rate care as 'highly positive'
When the Dundee team treated chemotherapy-resistant ovarian cancer cells grown in the lab with certain PARP inhibitors, they found the cells used ABCB1 to survive the treatment in the same way they do paclitaxel.
Dr Gillian Smith, who led the research, said: "Drug resistance is a major complication for many ovarian cancer patients.
"Our study shows an important resistance mechanism which is common to drugs used routinely in the clinic and to new drugs which are being tested in clinical trials.
"Increasing our understanding of resistance mechanisms will allow us to develop tests to spot drug resistance more easily and to make sure patients are given the most appropriate drugs.
Read more: Cancer patients 'more likely to survive if married'
"Understanding the biology of drug-resistant cancers could also lead to the development of new treatments that block cancer's escape, making them susceptible to therapy again."
The researchers also found that the paclitaxel chemotherapy-resistant cancer cells used ABCB1 to survive treatment with a different chemotherapy drug called doxorubicin, which is also offered to some women whose cancer has stopped responding.
The findings have been published in the British Journal of Cancer.
Nell Barrie, senior science information manager at Cancer Research UK, said: "This research increases our understanding of how drug resistance develops in ovarian cancer at a cellular level.
"It shows for the first time that the same mechanism that causes ovarian cancer to become resistant to paclitaxel also applies to some PARP inhibitors and other chemotherapy treatments.
Read more: Cancer rates soar by 14 per cent in a decade
"Further studies are now needed in patients to see whether some treatments will perform better than others at helping to control ovarian cancer."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here